SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Bratt Ola) "

Sökning: WFRF:(Bratt Ola)

  • Resultat 31-40 av 141
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
31.
  • Bratt, Ola (författare)
  • Familial and Hereditary Prostate Cancer
  • 1999
  • Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
    • This thesis is based on research concerning epidemiological, clinical, and psychological aspects of familial and hereditary prostate cancer. Epidemiology: Male first-degree relatives of prostate cancer patients had a three-fold increased prostate cancer risk. The risk was higher for relatives of younger patients than for relatives of older patients, most likely due to the effect of the higher prevalence of hereditary prostate cancer found among the former. For first-degree relatives of men with early onset prostate cancer, the risk of developing prostate cancer before the age of 70 years was increased 3.4 times, but their total cancer risk was not increased. Short CAG repeats in the androgen receptor gene correlated with early age at diagnosis of non-hereditary prostate cancer, but not with the risk of developing the disease per se. Clinical aspects: Patients with hereditary prostate cancer were diagnosed, on an average, 7 years earlier than those with sporadic prostate cancer. Family history of prostate cancer was not significantly associated with survival for patients with early onset disease. Psychological aspects: Most men with a family history of prostate cancer worried about the possibility of inheriting the disease. Almost all of them (90-94%) had positive attitudes towards genetic investigations, including genetic testing, and screening. Forty percent of unaffected men in families with hereditary prostate cancer substantially overestimated their lifetime risk of the disease. Perception of high risk was associated with symptoms of depression and cancer worries that affected daily living. High levels of cancerspecific stress may have counteracted participation in screening for some men.
  •  
32.
  • Bratt, Ola, et al. (författare)
  • Family History and Probability of Prostate Cancer, Differentiated by Risk Category : A Nationwide Population-Based Study
  • 2016
  • Ingår i: Journal of the National Cancer Institute. - : Oxford University Press (OUP). - 0027-8874 .- 1460-2105. ; 108:10
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Familial prostate cancer risk estimates are inflated by clinically insignificant low-risk cancer, diagnosed after prostate-specific antigen testing. We provide age-specific probabilities of non-low-and high-risk prostate cancer. Methods: Fifty-one thousand, eight hundred ninety-seven brothers of 32 807 men with prostate cancer were identified in Prostate Cancer data Base Sweden (PCBaSe). Nelson-Aalen estimates with 95% confidence intervals (CIs) were calculated for cumulative, family history-stratified probabilities of any, non-low-(any of Gleason score >= 7, prostate-specific antigen [PSA] >= 10 ng/mL, T3-4, N1, and/or M1) and high-risk prostate cancer (Gleason score >= 8 and/or T3-4 and/or PSA >= 20 ng/mL and/or N1 and/or M1). Results: The population probability of any prostate cancer was 4.8% (95% CI = 4.8% to 4.9%) at age 65 years and 12.9% (95% CI = 12.8% to 12.9%) at age 75 years, of non-low-risk prostate cancer 2.8% (95% CI = 2.7% to 2.8%) at age 65 years and 8.9% (95% CI = 8.8% to 8.9%) at age 75 years, and of high-risk prostate cancer 1.4% (95% CI = 1.3% to 1.4%) at age 65 years and 5.2% (95% CI = 5.1% to 5.2%) at age 75 years. For men with one affected brother, probabilities of any prostate cancer were 14.9% (95% CI = 14.1% to 15.8%) at age 65 years and 30.3% (95% CI = 29.3% to 31.3%) at age 75 years, of non-low-risk prostate cancer 7.3% (95% CI = 6.7% to 7.9%) at age 65 years and 18.8% (95% CI = 17.9% to 19.6%) at age 75 years, and of high-risk prostate cancer 3.0% (95% CI = 2.6% to 3.4%) at age 65 years and 8.9% (95% CI = 8.2% to 9.5%) at age 75 years. Probabilities were higher for men with a stronger family history. For example, men with two affected brothers had a 13.6% (95% CI = 9.9% to 17.6 %) probability of high-risk cancer at age 75 years. Conclusions: The age-specific probabilities of non-low-and high-risk cancer presented here are more informative than relative risks of any prostate cancer and more suitable to use for counseling men with a family history of prostate cancer.
  •  
33.
  •  
34.
  •  
35.
  •  
36.
  •  
37.
  •  
38.
  • Bratt, Ola, et al. (författare)
  • Metaphase cytogenetics and DNA flow cytometry with analysis of S-phase fraction in prostate cancer: influence on prognosis
  • 1996
  • Ingår i: Urology. - 1527-9995. ; 47:2, s. 218-224
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVES: To compare the prognostic significance of chromosome aberrations, DNA ploidy, and S-phase fraction (SPF) in prostate adenocarcinomas and to compare the sensitivity of metaphase cytogenetics with flow cytometry (FCM) in detecting abnormal tumor clones. METHODS: Prostate adenocarcinomas from 57 men were previously successfully analyzed with metaphase cytogenetics. Archival material from these tumors were further analyzed with FCM for DNA content and SPF. RESULTS: The patients were followed for 4.5 to 7.7 years. DNA ploidy was analyzed in 51, and SPF in 45 of the 57 tumors. Clonal chromosomal aberrations, DNA aneuploidy, and high SPF were all significantly associated with poor survival. Of these three variables, SPF was the best predictor of survival, but compared with tumor stage and grade in multivariate analysis, SPF was not an independent prognostic factor. Patients with locally advanced tumors or metastatic disease with SPF less than 8% had a median survival of 5.9 years, compared with only 1.3 years for those with SPF more than 8%. Twenty-eight abnormal clones were detected with FCM and 20 with cytogenetic analysis, but only for two of these clones could the results from the two different methods be regarded as concordant. CONCLUSIONS: SPF was superior to karyotype and ploidy in predicting death in prostate cancer, but it remains to be shown whether SPF analysis adds prognostic information to tumor stage and grade. The cytogenetic analyses correlated poorly with results of FCM, indicating low sensitivity of both methods.
  •  
39.
  •  
40.
  • Bratt, Ola, et al. (författare)
  • Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer.
  • 2009
  • Ingår i: British journal of cancer. - : Springer Science and Business Media LLC. - 1532-1827 .- 0007-0920. ; 101:8, s. 1233-40
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Tasquinimod is a quinoline-3-carboxamide derivative with anti-angiogenic activity. Two open-label phase I clinical trials in patients were conducted to evaluate the safety and tolerability of tasquinimod, with additional pharmacokinetic and efficacy assessments. METHODS: Patients with castration-resistant prostate cancer with no previous chemotherapy were enrolled in this study. The patients received tasquinimod up to 1 year either at fixed doses of 0.5 or 1.0 mg per day or at an initial dose of 0.25 mg per day that escalated to 1.0 mg per day. RESULTS: A total of 32 patients were enrolled; 21 patients were maintained for >or=4 months. The maximum tolerated dose was determined to be 0.5 mg per day; but when using stepwise intra-patient dose escalation, a dose of 1.0 mg per day was well tolerated. The dose-limiting toxicity was sinus tachycardia and asymptomatic elevation in amylase. Common treatment-emergent adverse events included transient laboratory abnormalities, anaemia, nausea, fatigue, myalgia and pain. A serum prostate-specific antigen (PSA) decline of >or=50% was noted in two patients. The median time to PSA progression (>25%) was 19 weeks. Only 3 out of 15 patients (median time on study: 34 weeks) developed new bone lesions. CONCLUSION: Long-term continuous oral administration of tasquinimod seems to be safe, and the overall efficacy results indicate that tasquinimod might delay disease progression.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 31-40 av 141
Typ av publikation
tidskriftsartikel (127)
forskningsöversikt (9)
konferensbidrag (3)
doktorsavhandling (2)
Typ av innehåll
refereegranskat (121)
övrigt vetenskapligt/konstnärligt (20)
Författare/redaktör
Bratt, Ola (81)
Bratt, Ola, 1963 (55)
Stattin, Pär (47)
Garmo, Hans (20)
Bill-Axelson, Anna (19)
Adolfsson, Jan (19)
visa fler...
Ahlgren, Göran (14)
Holmberg, Lars (13)
Lambe, Mats (11)
Damber, Jan-Erik, 19 ... (9)
Hugosson, Jonas, 195 ... (9)
Akre, Olof (9)
Johansson, Eva (8)
Liedberg, Fredrik (7)
Loeb, Stacy (7)
Johansson, Jan-Erik (7)
Garmo, H. (7)
Carlsson, S (6)
Stattin, P (6)
Adolfsson, J. (5)
Egevad, Lars (5)
Carlsson, Stefan (5)
Van Hemelrijck, Miek ... (5)
Lilja, Hans (4)
Lyttkens, Kerstin (4)
Kjölhede, Henrik, 19 ... (4)
Lambe, M (4)
Varenhorst, Eberhard (4)
Törnblom, Magnus (4)
Widmark, Anders (4)
Andrén, Ove (4)
Akre, O (4)
Godtman, Rebecka Arn ... (4)
Robinson, D. (3)
Almquist, Helen (3)
Montorsi, Francesco (3)
Berglund, Anders (3)
Andren, Ove, 1963- (3)
Damber, Jan-Erik (3)
Hellström, Magnus (3)
Holmberg, Erik (3)
Hugosson, Jonas (3)
Nilsson, Per (3)
Bjartell, Anders (3)
Jäderling, Fredrik (3)
Stranne, Johan, 1970 (3)
Fransson, Per (3)
Carlsson, Sigrid, 19 ... (3)
Jiborn, Thomas (3)
Wallström, Jonas (3)
visa färre...
Lärosäte
Lunds universitet (68)
Göteborgs universitet (64)
Uppsala universitet (37)
Umeå universitet (25)
Karolinska Institutet (14)
Örebro universitet (8)
visa fler...
Chalmers tekniska högskola (4)
Linköpings universitet (2)
Malmö universitet (1)
visa färre...
Språk
Engelska (132)
Svenska (9)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (138)
Naturvetenskap (2)
Teknik (2)
Lantbruksvetenskap (1)
Samhällsvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy